EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new study evaluating the use of AstraZeneca’s monoclonal antibody, Sopavibart (Kavigale), as a potential treatment for long COVID patients.
Long COVID continues to affect millions of people across the UK, leaving many unable to work or access effective treatment options. While Sopavibart (Kavigale) has been approved in the EU and imported into the UK by some private clinics, it remains cost-prohibitive for most patients, with treatments running into thousands of pounds per patient. Meanwhile, NHS services are overwhelmed, leaving many long COVID sufferers with no viable treatment options.
Attomarker has previously conducted a diagnostic classification study identifying key immune response patterns in long COVID patients:
- 60% show signs of immune compromise
- 15% exhibit a hyperactive immune response
- 25% have a normal antibody spectrum at the time of test.
For those in the immune-compromised category, monoclonal antibodies could offer a much-needed boost. The upcoming study, in collaboration with leading clinics, will track 30 patients receiving Sopavibart (Kavigale) to document its real-world impact on long COVID symptoms.
Access and Affordability Remain Key Barriers
Although monoclonal antibody treatments like Sopavibart (Kavigale) could help long COVID patients, they are currently only available in private clinics at significant cost, meaning the vast majority of long COVID patients are left without access to this treatment.
Many of those most affected by long COVID are unable to work, making self-pay options impossible. This study is a step towards ensuring access to treatment for those who need it most.
Attomarker is actively seeking funding to provide treatment to patients who cannot afford it. By securing financial backing, the study will help generate critical data while giving more patients access to a potentially life-changing therapy.
About Attomarker
Attomarker provides rapid point-of-care or postal blood testing that supports healthcare professionals in making precise, data-driven decisions for personalised patient care. To learn more about Attomarker, visit www.attomarker.com.
Contact
Suzanne Gaunt, suzanne.gaunt@attomarker.com
Can I sign up for this trial?
I have long covid.
Thank you.
Thank you for expressing an interest in the trial, recruitment has not started. Please sign up to notifications from Attomarker to stay up to date.